FDA-Approved Medications for Autism-Related Irritability in 16-17 Year-Olds
Both risperidone and aripiprazole are FDA-approved for treating irritability associated with autism spectrum disorder in adolescents aged 16-17 years. These are the only two medications with this specific FDA indication for this age group 1, 2.
Evidence Base
The AACAP guidelines clearly identify both agents as FDA-approved for irritability in autism, which consists primarily of physical aggression and severe tantrum behavior 1. The evidence demonstrates:
Risperidone
- Efficacy: 69% positive response rate vs. 12% on placebo in children 5-17 years old 1
- Dosing: 0.5-3.5 mg/day
- Side effects: Weight gain, increased appetite, fatigue, drowsiness, drooling, dizziness 1
- Significant improvements in irritability, hyperactivity, and stereotypy subscales
Aripiprazole
- Efficacy: 56% positive response at 5 mg dose vs. 35% on placebo in children 6-17 years old 1
- Dosing: 5-15 mg/day (flexibly dosed)
- Side effects: Somnolence, weight gain, drooling, tremor, fatigue, vomiting 1
- Significant improvements in irritability, hyperactivity, and stereotypy subscales
Recent meta-analysis confirms aripiprazole significantly reduces irritability (mean difference = -5.18 on ABC-I scale) with manageable adverse effects 3.
Clinical Decision-Making
Head-to-head comparison shows equivalent efficacy and safety between the two agents 4. The choice should be based on:
- Metabolic risk profile: Risperidone carries greater metabolic burden (weight gain) than aripiprazole 2, 5
- Extrapyramidal symptoms: Aripiprazole has lower probability of EPS 6
- Prior medication response: If family history suggests better response to one agent
Important Clinical Considerations
Combining medication with parent training is moderately more efficacious than medication alone for decreasing serious behavioral disturbance 1. Do not use pharmacotherapy in isolation.
Common Pitfalls to Avoid
- Starting without clear target symptoms (aggression, self-injury, severe tantrums)
- Failing to monitor metabolic parameters (weight, lipids, glucose)
- Not using objective rating scales (ABC-Irritability subscale) to track response
- Neglecting behavioral interventions as the foundation of treatment
Monitoring Requirements
- Use standardized scales (Aberrant Behavior Checklist-Irritability subscale) to document response 1
- Monitor weight, metabolic parameters, and movement disorders regularly
- Assess whether medication facilitates engagement with educational interventions—this is the ultimate treatment goal 1
Both medications reduce 30-day and 90-day readmission rates in this population 7, supporting their real-world effectiveness for severe, persistent irritability.